Why the study?
CKM syndrome causes substantial morbidity and mortality despite guideline-directed therapy, with nitric oxide pathway dysfunction representing a unifying mechanism of residual risk.
Design
Review
Key result
Therapeutic modulation of nitric oxide pathways provides a biologically coherent model for addressing residual cardiometabolic risk, though outcome-level evidence is currently lacking.
Authors
Loading...
Supports NO pathway targeting in CKM syndrome; extends mechanistic integration across obesity, diabetes, CKD, and CVD.
Targeting nitric oxide pathway dysfunction offers a potential therapeutic framework to address residual cardiovascular and renal risk in cardiovascular-kidney-metabolic syndrome.
Ceteraș et al. (2026) conducted a review in Cardiovascular-kidney-metabolic (CKM) syndrome. Nitric oxide pathway modulation was evaluated. Therapeutic modulation of nitric oxide pathways provides a biologically coherent model for addressing residual cardiometabolic risk, though outcome-level evidence is currently lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: